Table 2.
| Treatment | Mortality | Major Complications | mOS | 5 Years Survival |
|---|---|---|---|---|
| RFA | 0.1–05% | 2.2–4.1% | 21 months | 59.8% |
| MWA | 0–0.36% | 2.6–4.6% | 31 months | 67.9% |
| PEI | 0.6 | 0–3.2% | NA | 47–53% |
| CA | 0% | 2.8–3.9% | NA | 59.5% |
| IRE | 0% | 3.3–4.7% | 26.3 | NA |
| TACE | 1% | 2.1–5% | 38.3 | 27.6% |
| DEB-TACE | 1.2% | 3.2% | 37 | 22.5% |
| SIRT | 1.5% | 4.9% | 10–29 | NA |
mOS: median overall survival; RFA: radiofrequency thermal-ablation; MWA: microwave ablation; PEI: percutaneous ethanol injection; CA: cryoablation; IRE: irreversible electroporation; TAE: transarterial embolization; TACE: transarterial chemoembolization; DEB-TACE: transarterial chemoembolization with drug-eluting beads; SIRT: selective internal radiation therapy.